Viking Therapeutics stock rose 87% on results for its liver disease drug — and the company has more in store this fall
September 18, 2018 at 16:55 PM EDT
The company’s midstage clinical trial had positive results, and the condition in question affects an estimated 100 million people in the U.S.
